Rivastigmine

Generic Name
Rivastigmine
Brand Names
Exelon, Nimvastid, Prometax, Rivastigmine Sandoz, Rivastigmine 1 A Pharma, Rivastigmine Hexal, Rivastigmine Actavis
Drug Type
Small Molecule
Chemical Formula
C14H22N2O2
CAS Number
123441-03-2
Unique Ingredient Identifier
PKI06M3IW0
Background

Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.

Indication

For the treatment of mild to moderate dementia associated with Parkinson's disease or of the Alzheimer's type.

Associated Conditions
Dementia With Lewy Body Disease, Mild Dementia due to Parkinson's disease, Mild Dementia of the Alzheimer's Type, Moderate Alzheimer's Type Dementia, Moderate Dementia due to Parkinson's disease
Associated Therapies
-
Clinical Trials
Related News

Efficacy of Rivastigmine in Patients With Down Syndrome

Not Applicable
Completed
Conditions
Down Syndrome
Interventions
Drug: Rivastigmine
First Posted Date
2008-09-08
Last Posted Date
2012-11-28
Lead Sponsor
National Taiwan University Hospital
Target Recruit Count
14
Registration Number
NCT00748007
Locations
🇨🇳

Department of Medical Genetics, National Taiwan University Hospital, Taipei, Taiwan

Rivastigmine for Intensive Care Unit (ICU) Delirium

Phase 4
Terminated
Conditions
Delirium
Interventions
Drug: Placebo
Drug: Rivastigmine
First Posted Date
2008-06-24
Last Posted Date
2010-08-13
Lead Sponsor
UMC Utrecht
Target Recruit Count
104
Registration Number
NCT00704301
Locations
🇳🇱

Medical Center Leeuwarden, Leeuwarden, Friesland, Netherlands

🇳🇱

Gelre Hospitals; lukas site, Apeldoorn, Gelderland, Netherlands

🇳🇱

Erasmus Medical Center, Rotterdam, Zuid-Holland, Netherlands

and more 3 locations

Rivastigmine in Mild Alzheimer's Disease, FMRI Study

Not Applicable
Completed
Conditions
Alzheimer' Disease
First Posted Date
2008-03-03
Last Posted Date
2011-10-28
Lead Sponsor
Kuopio University Hospital
Target Recruit Count
20
Registration Number
NCT00627848
Locations
🇫🇮

Kuopio University Hospital, Kuopio, Finland

A Double-Blind, Placebo-controlled Crossover Study of Repeat Rivastigmine Administration in Healthy Male Volunteers

Not Applicable
Completed
Conditions
Rivastigmine Toxicity
Interventions
Drug: Rivastigmine
First Posted Date
2008-02-27
Last Posted Date
2014-03-27
Lead Sponsor
Tel-Aviv Sourasky Medical Center
Target Recruit Count
15
Registration Number
NCT00624663
Locations
🇮🇱

Tasmc Clinical Research Center, Tel-Aviv, Israel

🇮🇱

Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

Methylphenidate, Rivastigmine or Haloperidol in Hypoactive Delirium in Intensive Care Patients

First Posted Date
2008-01-23
Last Posted Date
2018-03-21
Lead Sponsor
UMC Utrecht
Target Recruit Count
80
Registration Number
NCT00599287
Locations
🇳🇱

University Medical Center, Utrecht, Netherlands

Efficacy Study for Treatment of Dementia in Progressive Supranuclear Palsy

First Posted Date
2007-08-29
Last Posted Date
2008-02-18
Lead Sponsor
University Hospital Tuebingen
Target Recruit Count
20
Registration Number
NCT00522015
Locations
🇩🇪

University of Tuebingen, Tuebingen, Baden Wuerttemberg, Germany

An Extension Study Evaluating the Efficacy and Safety of Rivastigmine in Patients With Traumatic Brain Injury (TBI) With Persistent Cognitive Deficits

First Posted Date
2005-09-22
Last Posted Date
2011-11-17
Lead Sponsor
Novartis
Target Recruit Count
157
Registration Number
NCT00219245

Efficacy and Safety of Rivastigmine in Patients With Traumatic Brain Injury and Cognitive Impairment

Phase 3
Completed
Conditions
Traumatic Brain Injury
First Posted Date
2005-09-15
Last Posted Date
2011-11-23
Lead Sponsor
Novartis
Target Recruit Count
67
Registration Number
NCT00171795

Rivastigmine For Methamphetamine Dependent Individuals

Phase 1
Completed
Conditions
Substance-Related Disorders
First Posted Date
2005-09-12
Last Posted Date
2017-01-12
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Target Recruit Count
18
Registration Number
NCT00158210
Locations
🇺🇸

University of California - Los Angeles, Los Angeles, California, United States

Efficacy and Safety of Rivastigmine in Patients With Mild Cognitive Impairment

Phase 3
Terminated
Conditions
Cognitive Symptoms
First Posted Date
2005-08-25
Last Posted Date
2007-12-17
Lead Sponsor
Novartis
Target Recruit Count
24
Registration Number
NCT00134953
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy